Sharekhan

Sun Pharma Advanced Research Company Ltd

Tue 29/04/2025,12:34:57 NSE: SPARC

₹ 149.20 -1.36 (-0.90%)
BUY NOW Buy Sun Pharma Advanced Research Company Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Sun Pharma Advanced Research Company Ltd

Tue 29/04/2025,12:42:0

Sun Pharma Advanced Research Company Ltd

Tue 29/04/2025,12:34:57 | NSE : SPARC

₹ 149.20-1.36 (-0.90%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 152.00

Previous Close

₹ 150.56

Volume

194853

Mkt Cap ( Rs. Cr)

₹4841.86

High

₹ 153.54

Low

₹ 148.52

52 Week High

₹ 258.00

52 Week Low

₹ 109.30

Book Value Per Share

₹ -2.38

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Sun Pharma Advanced Research Company Ltd

Your Vote -

Buy

69.64%

Hold

6.25%

Sell

24.11%

69.64%

112 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

28%

Sell Order Quantity

72%

Bid Price

Qty

149.00

95

149.00

100

149.00

6

149.00

17

149.00

25

Bid Total

57610

Bid Price

Qty

149.09

19

149.00

2

149.00

13

149.00

22

149.00

32

Bid Total

150995

Option Chain

Analyzes market sentiment, predicts Sun Pharma Advanced Research Company Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sun Pharma Advanced - Disclosure under SEBI Takeover Regulations

    24 Apr 2025, 5:49PM Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial

  • Sun Pharma Advanced has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:31PM As of March 2025, 65.68% is owned by Indian Promoters and 34.33% by Public. <p align=justify> Top five Promoters holding highest number of shares of S

  • Sun Pharma Advanced - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Apr 2025, 6:59PM Sun Pharma Advanced Research Company Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Sun Pharma Advanced - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Apr 2025, 6:25PM Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

  • Sun Pharma Advanced - Press Release

    31 Mar 2025, 8:37AM Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated March 31, 2025, titled ""Press Release about su

  • Sun Pharma Advanced - Trading Window-XBRL

    27 Mar 2025, 11:58AM Sun Pharma Advanced Research Company Limited has informed the Exchange about Closure of Trading Window

  • Sun Pharma Advanced - Trading Window

    27 Mar 2025, 11:56AM Sun Pharma Advanced Research Company Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider T

  • Sun Pharma Advanced - Price movement

    25 Mar 2025, 7:04PM Significant movement in price has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have

  • Sun Pharma Advanced - Clarification On Price Movement

    25 Mar 2025, 6:46PM Clarification on Price Movement

  • Sun Pharma Advanced - Price movement

    25 Mar 2025, 5:11PM Significant movement in price has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have

  • Sun Pharma Advanced - Clarification sought from Sun Pharma Advanced Research Company Ltd

    25 Mar 2025, 5:14PM The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on March 25, 2025 with reference to significant movement in price,

  • Sun Pharma Advanced - Credit Rating- Revision

    5 Mar 2025, 7:37PM Sun Pharma Advanced Research Company Limited has informed the Exchange about Credit Rating- Revision

  • Sun Pharma Advanced - Announcement under Regulation 30 (LODR)-Credit Rating

    5 Mar 2025, 7:29PM Intimation regarding credit rating

  • Sun Pharma Advanced - Copy of Newspaper Publication

    12 Feb 2025, 12:49PM Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication pertaining to financial results of Q3 FY 25

  • Sun Pharma Advanced - Integrated Filing (Financial)

    10 Feb 2025, 8:11PM Integrated filing (Financial) for the quarter and nine months ended December 31, 2024

  • Sun Pharma Advanced - Integrated Filing- Financial

    10 Feb 2025, 8:10PM Integrated Financials

  • Sun Pharma Advanced posts Q3 net loss of Rs 79.71 cr

    10 Feb 2025, 8:00PM The company reported standalone net loss during the quarter stood at Rs 79.71 crore as compared to net loss of Rs 99.65 crore in the previous year qua

  • Sun Pharma Advanced - Outcome of Board Meeting

    10 Feb 2025, 8:00PM Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Outcome of Board Meeting held on February 10, 2025.

  • Sun Pharma Advanced - Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 10, 2025

    10 Feb 2025, 8:00PM Outcome of the Board Meeting

  • Sun Pharma Advanced - Financial Results For The Quarter And Nine Months Ended December 31, 2024

    10 Feb 2025, 7:57PM Financial Results for the quarter and nine months ended December 31, 2024

  • Sun Pharma Advanced - Financial Result Updates

    10 Feb 2025, 7:56PM Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.

  • Sun Pharma Advanced - Board Meeting Intimation

    31 Jan 2025, 4:02PM SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED has informed the Exchange about Board Meeting to be held on 10-Feb-2025 to inter-alia consider and approv

  • Sun Pharma Advanced - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Nine Months En

    31 Jan 2025, 3:55PM SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 ,inter

  • SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB

    2 Nov 2023 , 10:14AM SPARC had evaluated SCD-153 under a Material Transfer Agreement

  • Sun Pharma Advanced Research Company

    14 Jul 2023 , 10:26AM Announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PDP-716 for the treatment of patients with Glaucoma, due to inspection findings at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility. Positive for the stock.

  • SPARC gets USFDA nod for SEZABY for the treatment of Neonatal Seizures

    18 Nov 2022 , 10:06AM SEZABY approves by USFDA for the treatment of neonatal seizures

  • Sun Pharma arm clocks decent Q3 numbers

    7 Feb 2022 , 12:55PM Revenues grow y-o-y; loss reduces substantially

  • SPARC to present updated clinical data of vodobatinib

    10 Dec 2021 , 3:23PM SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

  • SPARC inks deal with Biomodifying

    3 Dec 2021 , 2:36PM SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

  • SPARC

    2 Sep 2021 , 9:45AM The board has approved raising of funds amounting to Rs 1800 cr through a combination of securities in one or more tranches by way of public / private offerings, qualified institutional placements, rights offerings. Also the board at the meeting has approved to increase the authorized capital of the company from Rs 37.50 cr to RS 42.50 crores.

  • Sun Pharma Advanced Research

    1 Sep 2021 , 9:59AM The company has scheduled a board meeting today to consider and evaluate various options / proposals for raising funds through any of the permissible modes.

  • Sun Pharma Advanced Research Company

    24 Feb 2021 , 11:23AM The USFDA has ruled against the company’s appeal for a CRL (complete response letter)related to Taclantis, its under development product for treatment of cancer. In the letter, the regulator has requested to conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis NDA. This would be a negative development for the company as the product launch could be delayed

  • SPARC reports positive top-line results from its Phase 3 trial

    14 Oct 2020 , 9:43AM SPARC announces positive top-line results from Pivotal Phase 3 Clinical Trial of SDN-037 for the treatment of inflammation and pain associated with Ocular Surgery

  • SPARC grant an exclusive license to Tripoint Therapeutics

    22 Sep 2020 , 11:45AM SPARC licenses commercialization rights of Elepsia TM XR to Tripoint Therapeutics

  • SPARC declines as USFDA rejects cancer drug application

    12 Feb 2020 , 11:07AM SPARC falls by 10.7% to Rs. 171.9, after US drug regulator rejects the company's cancer drug application for Taclantis in its current form

  • SPARC

    12 Feb 2020 , 10:33AM SPARC has received a complete response letter from the USFDA, wherein the regulator has not approved the company’s application for novel Paclitaxle injection – Taclantis, in the current form. This is negative for SPARC and Sun Pharma

  • SPARC up after Abraxis dismisses complaint

    9 Dec 2019 , 12:18PM SPARC rises by 5% to Rs. 162.4, after Abraxis Bioscience dismissed patent infringement complaint filed against the company

  • SPARC enters into a licensing deal with CMS

    6 Nov 2019 , 11:30AM SPARC enters into a Licensing Deal with China Medical System Holding Limited (CMS)

  • Abraxis Biosciences files plea against SPARC

    21 Aug 2019 , 11:06AM Sun Pharma Advanced Research (SPARC): As per media reports, a complaint has been filed by Abraxis Biosciences in the U.S. Court alleging the company’s filing of new drug application for Taclantis injection infringes patents for Abraxane - Negative; Outcome of court ruling will be crucial monitorable.

  • SPARC gets orphan drug designation from USFDA for SCO-088

    8 Jul 2019 , 12:28PM SPARC gets orphan drug designation from USFDA for SCO-088. It is used for treatment of patients with Chronic Myeloid Leukemia

  • SPARC enters into a research collaboration with HitGen

    13 Mar 2019 , 12:25PM Sun Pharma Advanced Research Company Ltd. (SPARC) enters into a research collaboration with HitGen to identify novel small molecule leads for targets of interest – Positive read thru.

  • SPARC enters into research collaboration with HitGen

    13 Mar 2019 , 10:21AM SPARC announces research collaboration with HitGen, a Chinese company

  • SPARC gets GST notice for Rs. 46.04 crore

    8 Feb 2019 , 11:16AM SPARC gets a demand order worth Rs. 46.04 crore for payment of Service Tax

  • Sun Pharma: Speciality business to gain traction in US

    6 Sep 2018 , 1:07PM Sun Pharma highlighted that it expects the USFDA to approve two of its key drugs (Xelpros & Elepsia) by the second half (Nov-18 and Jan -19 resp) of this financial year

  • SPARC has TAD from USFDA to review 2 new drugs

    5 Sep 2018 , 10:54AM Sun Pharma Advanced Research (SPARC) has Target Action Date (TAD) from the USFDA to review its two new drugs ‘Xelpros’ and ‘Elepsia’ as November 2018 and January 2019, respectively; SPARC will shift its research facility to Vadodara and file a new drug application for its cancer drug ‘Taclantis’ in Q4FY2019 – Positive; Sun Pharma to be in focus as it is manufacturing partner for Xelpros and Elepsia which are filed from Halol.

  • One-off tax expenses dent profit for Sun Pharma

    15 Feb 2018 , 12:02PM We maintain our Hold recommendation on the stock (as Halol resolution could act as a positive trigger) with a price target (PT) of Rs. 600, valuing the stock at 20x its FY2020E earnings.

  • Sun Pharma owned Taro reports weak Q3FY18 results

    8 Feb 2018 , 10:05AM Negative read through for Sun Pharma as Halol plant to undergo USFDA re-inspection from Feb 12, 2018, so stock to remain in focus.

  • Sun Pharma's Ankleshwar plant catches major fire

    5 Feb 2018 , 9:46AM Negative read through for Sun Pharma as its Ankleshwar plant catches major fire with a blast.

  • Sun Pharma gets USFDA approval for Metoprolol succinate capsules

    31 Jan 2018 , 9:41AM Positive for Sun Pharma as it gets USFDA approval for Metoprolol succinate capsules, used to treat chest pain (angina), heart failure, and high blood pressure.

  • Sun Pharma gets a license to sell the generic version of Linzess

    17 Jan 2018 , 9:38AM Sentimental Positive for Sun Pharma as it gets a license to sell the generic version of Linzess (Linaclotide capsules – used to treat bowel conditions) in US from Feb 01.

  • USFDA to re-inspect Sun Pharma's Halol manufacturing facility

    8 Jan 2018 , 9:08AM Stock to remain in focus as USFDA is likely to re-inspect Sun Pharma’s Halol manufacturing facility in the second week of February.

  • Can Sun shine again in 2018?

    2 Jan 2018 , 9:48AM Sun Pharma recently announced that the USFDA has accepted its New Drug Application (NDA) for OTX-101 (cyclosporine A, Ophthalmic solution), marking an important developmental milestone for Sun Pharma’s dry eye candidate.

  • Sun Pharma announces USFDA acceptance of NDA

    27 Dec 2017 , 10:24AM Positive for Sun Pharma as Sun Pharma announces USFDA acceptance of New Drug Application (NDA) for OTX-101, used for treatment of dry eye disease

  • SPARC drops as it fails to meet primary end points

    9 Oct 2017 , 2:23PM SPARC declined nearly 15% to Rs332, after the company announced the top-line results of the Phase III efficacy study and duration of action study for Baclofen GRS

  • Sun Pharma's research arm fails to meet phase 3 end pts

    9 Oct 2017 , 10:01AM Sun Pharma’s research arm Sun Pharma Advanced Research Company’s (SPARCs) Baclofen GRS (used to treat spasticity in patients with multiple sclerosis) fails to meet Phase 3 end points – Negative for SPARC and Sun Pharma;
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Sun Pharma Advanced Research Company Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 171.8573 512.8261 106.2257 28.4635 49.161
Liabilities 171.8573 512.8261 106.2257 28.4635 49.161
Equity 32.453 32.453 27.1887 26.2056 26.2056
Gross Profit -403.7917 -214.0554 -186.7494 -134.9777 -310.0108
Net Profit -388.1052 -222.5835 -203.3954 -151.1388 -312.4034
Cash From Operating Activities -429.4264 -69.1179 -208.2325 -151.8956 -210.8054
NPM(%) -513.73 -93.21 -148.19 -59.74 -406.69
Revenue 75.5453 238.7801 137.2489 252.9571 76.8144
Expenses 479.337 452.8355 323.9983 387.9348 386.8252
ROE(%) 501.57 287.65 262.86 195.32 403.73

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Sun Pharma Advanced Research Company Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 837.00 -0.23 11.81 86.06 1321.50 1.37
Lotus Eye Hospital and Institute Ltd 80.44 1.77 335.17 313.61 14.01 0.62
Vaishali Pharma Ltd 13.66 -0.58 455.33 161.65 2.76 0.00
Astec Lifesciences Ltd 691.75 -1.80 0.00 295.71 -687.11 0.00

Company Info

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN) 2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg. 2018 -SPARC to provide progress on R&D Pipeline -Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension -SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension -Schr”dinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program 2019 -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational -HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration -SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia -SPARC Enters into a Licensing Deal with CMS -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 2020 -Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA. -Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery -SPARC to Provide Update on Clinical Programs and R&D Pipeline 2021 -SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target -Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037 2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US. 2023 -Entered into licensing agreement to acquire exclusive rights for SCD-153. -Formation of US subsidiary.

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN) 2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg. 2018 -SPARC to provide progress on R&D Pipeline -Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension -SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension -Schr”dinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program 2019 -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational -HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration -SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia -SPARC Enters into a Licensing Deal with CMS -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 2020 -Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA. -Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery -SPARC to Provide Update on Clinical Programs and R&D Pipeline 2021 -SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target -Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037 2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US. 2023 -Entered into licensing agreement to acquire exclusive rights for SCD-153. -Formation of US subsidiary.

Read More

Parent Organisation

Sun Pharma Advanced Research Company Ltd.

Founded

01/03/2006

Managing Director

NSE Symbol

SPARCEQ

FAQ

The current price of Sun Pharma Advanced Research Company Ltd is ₹ 149.20.

The 52-week high for Sun Pharma Advanced Research Company Ltd is ₹ 153.54 and the 52-week low is ₹ 148.52.

The market capitalization of Sun Pharma Advanced Research Company Ltd is currently ₹ 4841.86. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Sun Pharma Advanced Research Company Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Sun Pharma Advanced Research Company Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sun Pharma Advanced Research Company Ltd shares.

The CEO of Sun Pharma Advanced Research Company Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT